Summary: The Centers for Medicare & Medicaid Services modified its FDG PET coverage policy for thyroid cancer, effective May 15, 2026, retiring the standalone policy and folding it into Section 220.6.17 of the National Coverage Determinations Manual. Here's what billing teams need to do before that date.
This change affects any practice or facility billing FDG PET scans for thyroid cancer patients under Medicare. The standalone policy has been retired — it no longer exists as a separate document. Coverage is now governed entirely by Section 220.6.17. The policy does not list specific CPT or HCPCS codes in the available data, but your PET imaging billing workflow is directly in scope.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | FDG PET for Thyroid Cancer — RETIRED, Replaced by Section 220.6.17 |
| Policy Code | N/A |
| Change Type | Modified (Retirement / Consolidation) |
| Effective Date | May 15, 2026 |
| Impact Level | Medium — affects documentation, prior authorization workflows, and payer correspondence for thyroid cancer PET billing |
| Specialties Affected | Nuclear medicine, radiology, oncology, endocrinology billing teams |
| Key Action | Update all internal policy references, coverage determination lookups, and prior auth forms to point to Section 220.6.17 before May 15, 2026 |
CMS FDG PET Thyroid Cancer Coverage Criteria and Medical Necessity Requirements 2026
The real change here is structural, not clinical. CMS isn't necessarily rewriting the coverage rules from scratch. It is retiring a standalone coverage policy and consolidating thyroid cancer FDG PET coverage under Section 220.6.17 of the National Coverage Determinations Manual.
What that means for your team: the medical necessity criteria your billing staff cited in prior authorization requests, appeal letters, and claim documentation were tied to the old standalone policy. After May 15, 2026, those references are obsolete.
Your documentation needs to point to Section 220.6.17. If your appeals templates, ABN workflows, or prior auth forms cite the retired policy, a payer reviewer or Medicare Administrative Contractor auditor will notice. That's an unnecessary exposure point.
On the medical necessity side, FDG PET for thyroid cancer has historically covered specific clinical scenarios under CMS — primarily for differentiated thyroid cancer that is thyroglobulin-positive but radioiodine scan-negative. That medical necessity framework doesn't vanish when a policy retires. It migrates. Section 220.6.17 is now the authoritative home for those criteria.
Because no updated code-level data is available in the current policy record, your compliance officer or billing consultant should pull the full text of Section 220.6.17 directly from the CMS NCD Manual before May 15. Verify whether any clinical criteria, coverage indications, or documentation requirements shifted during the consolidation. Don't assume it's a clean copy-and-paste.
Prior authorization requirements for FDG PET in thyroid cancer vary by Medicare Administrative Contractor. The retirement of the standalone policy doesn't change your MAC's local policies, but it does change which national authority you cite. Confirm with your MAC whether any prior auth forms require updated NCD citations after the effective date.
CMS FDG PET Thyroid Cancer Exclusions and Non-Covered Indications
The available policy data doesn't list specific exclusions. That's not unusual for a retirement/consolidation action — the exclusions migrate with the clinical criteria into Section 220.6.17.
What you need to watch: historically, CMS did not cover FDG PET for thyroid cancer in all presentations. Coverage was tied to specific clinical circumstances — particularly where conventional imaging failed and thyroglobulin elevation suggested recurrence. Routine staging, surveillance in low-risk patients, and initial diagnosis were not covered indications under the prior framework.
Those exclusions almost certainly carry forward into Section 220.6.17. But "almost certainly" isn't good enough when you're filing claims. Audit the new section directly. If a non-covered indication is now listed differently — or if the language tightened or loosened — your billing team needs to know before May 15.
If you're billing FDG PET for thyroid cancer patients on the edge of coverage criteria, this consolidation is the right moment to review those cases with your medical director. A policy retirement and re-consolidation is exactly the kind of change that creates claim denial exposure if teams assume nothing substantive shifted.
Coverage Indications at a Glance
The available policy data does not include indication-level coverage criteria. The table below reflects the historical CMS coverage framework for FDG PET in thyroid cancer — which migrates to Section 220.6.17 — based on the established NCD structure. Verify all indications against the full Section 220.6.17 text before May 15, 2026.
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Differentiated thyroid cancer — thyroglobulin-positive, radioiodine scan-negative | Covered (historically) | See Section 220.6.17 | Core covered indication under prior NCD; verify continuation in 220.6.17 |
| Routine initial staging of thyroid cancer | Not covered (historically) | See Section 220.6.17 | Not a supported indication under prior framework; confirm in 220.6.17 |
| Surveillance in low-risk differentiated thyroid cancer | Not covered (historically) | See Section 220.6.17 | Standard exclusion; verify in 220.6.17 |
| Medullary or anaplastic thyroid cancer | Coverage varies | See Section 220.6.17 | Prior framework limited; confirm updated status in 220.6.17 |
| Recurrence evaluation — conventional imaging inconclusive | Covered under CED historically | See Section 220.6.17 | Coverage with Evidence Development rules may apply; verify |
Note: This table is based on the historical NCD framework prior to the May 15, 2026 retirement. The controlling document after that date is Section 220.6.17. Do not cite the retired policy in claims or appeals after May 15.
CMS FDG PET Thyroid Cancer Billing Guidelines and Action Items 2026
The clock is running. Here's what your team needs to do before May 15, 2026.
| # | Action Item |
|---|---|
| 1 | Pull Section 220.6.17 now. Get the full text directly from the CMS NCD Manual. Read it against the retired policy. Flag any language that changed — in coverage criteria, documentation requirements, or covered indications. Don't rely on a summary. Read the source. |
| 2 | Update every internal reference to the retired policy. Your charge capture workflows, prior auth forms, medical necessity checklists, ABN templates, and appeals letter libraries all need to point to Section 220.6.17 after May 15. Audit every document that cites the old FDG PET thyroid cancer policy and replace the reference. |
| 3 | Notify your prior authorization team before May 15. If your staff submits prior auth requests for FDG PET in thyroid cancer patients, they need to cite the correct NCD. A prior auth submitted with a retired policy citation creates unnecessary friction with payers — and some reviewers will flag it. |
| 4 | Check your MAC's local coverage determinations. The national policy retirement doesn't automatically update your Medicare Administrative Contractor's local policies. Contact your MAC or check their LCD database to confirm whether any local documentation requirements changed in response to the Section 220.6.17 consolidation. |
| 5 | Review pending and in-flight claims. If you have FDG PET thyroid cancer claims currently in process or under appeal, confirm which policy version applies based on the date of service. Claims dated before May 15, 2026, fall under the retired policy. Claims dated May 15 and after fall under Section 220.6.17. |
| 6 | Train your billing team on the transition. This isn't a clinical change — it's an administrative one. But administrative changes cause claim denials when teams don't know about them. Run a brief update for anyone who touches FDG PET billing or thyroid cancer cases before the effective date. |
| 7 | Loop in your compliance officer if you have high FDG PET volume. If thyroid cancer PET imaging is a significant part of your revenue, a policy consolidation like this warrants a formal review. Your compliance officer should document that you reviewed Section 220.6.17 and confirmed your billing practices align before May 15. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for FDG PET Thyroid Cancer Under Section 220.6.17
The available policy data does not list specific CPT, HCPCS, or ICD-10 codes. This is a retirement and consolidation action — code-level details are embedded in Section 220.6.17 of the CMS NCD Manual.
Do not use this absence as a reason to skip the code audit. FDG PET imaging billing typically involves specific PET procedure codes and radiopharmaceutical supply codes. The ICD-10-CM diagnosis codes for thyroid cancer — including malignant neoplasm codes and post-procedural surveillance codes — determine whether the claim meets medical necessity under the NCD.
Pull the full code list from Section 220.6.17 directly. Confirm that every CPT and HCPCS code your team currently uses for FDG PET in thyroid cancer patients is still valid under the consolidated policy. Confirm the ICD-10-CM codes that support medical necessity still map correctly to the covered indications in Section 220.6.17.
If there's any discrepancy between what you're billing today and what Section 220.6.17 supports, fix it before May 15. A reimbursement disruption caused by a citation to a retired policy is entirely avoidable.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.